Rezolute, Inc. (AntriaBio, Inc.) — Form 10-Q Summary
Filing identity: The supplied filing is for AntriaBio, Inc., not Rezolute, Inc. It covers the quarter and nine months ended March 31, 2017; the quarter was the company’s fiscal third quarter. Financial statements are unaudited.
Business context and reporting period
AntriaBio described itself as a preclinical-stage biopharmaceutical company with no revenue. Its near-term priority was to prepare AB101, a potential once-weekly basal insulin, for a planned first-in-human Phase 1 study. The company reported manufacturing and filling AB101 vials and engaging a contract research organization for study start-up.
Key financial metrics
| Metric | Three months ended March 31, 2017 | Nine months ended March 31, 2017 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $5.39 million | $14.10 million |
| Net loss | $5.38 million | $14.09 million |
| Net loss attributable to common stock | $8.75 million | $17.45 million |
| Operating cash used | Not stated for quarter | $9.67 million |
The larger common-stock-attributable loss includes a $3.37 million deemed dividend from warrant modifications; it was not an operating cash expense. Gross margin is not meaningful because the company had no revenue.
At March 31, 2017, cash was $4.44 million, working capital was $2.83 million, total assets were $10.80 million, and stockholders’ equity was $8.46 million. Current liabilities were $2.02 million. Convertible notes payable were $10,000; the remaining notes had matured and were due, with interest accruing at 8%. Nine-month investing cash use was $0.11 million, financing cash provided was $10.16 million, and cash increased by $0.37 million.
Changes versus the prior comparable period
- Quarterly net loss increased from $3.71 million to $5.38 million; nine-month net loss increased from $11.06 million to $14.09 million.
- Nine-month research and development expense rose from $6.80 million to $9.00 million, primarily due to hiring and clinical-material manufacturing and trial start-up costs.
- Nine-month general and administrative expense rose from $4.28 million to $5.10 million, mainly reflecting higher legal and patent-related professional fees.
- Cash used in operations increased from $7.34 million to $9.67 million. Cash at period-end was $4.44 million, compared with $1.75 million a year earlier.
- Common shares issued and outstanding increased to 45.45 million from 35.11 million at June 30, 2016, reflecting equity financing and note conversion.
Outlook, risks, contingencies and unusual items
- Management planned to file an IND for AB101 with the FDA in June 2017, start the Phase 1 study afterward, and target interim data before the end of calendar 2017. These were plans, not assured outcomes.
- The company expected to seek proof of concept in animals for at least one pipeline candidate by year-end 2017, with a view to beginning IND-enabling work in 2018.
- Management reported approximately $6.7 million raised in calendar 2017 and targeted at least $15 million total to support operations into the first half of 2018. The filing also reports $2.2 million of additional gross proceeds received May 4, 2017, after quarter-end. Management warned that financing may not be available on acceptable terms or at all.
- The filing states that cash and expected operating cash flows would not sustain operations for more than one year and that substantial doubt existed about the company’s ability to continue as a going concern. Continued operations depended on additional financing.
- A shareholder derivative lawsuit concerning governance and stock-option grants was settled subject to Delaware Chancery Court approval. Related May 2017 agreements canceled options, including 11.09 million options under the 2016 plan and 1.17 million options granted in 2013; certain executive option awards were also amended.
- Management concluded disclosure controls were ineffective because of a material weakness involving insufficient segregation of duties, a need for a stronger control environment, and limited review of complex accounting issues. No material change in internal control over financial reporting was reported during the quarter.
- The company entered a new office lease and subleased part of its existing space. Future minimum lease commitments, net of stated sublease income, totaled $1.74 million.
- Risks include clinical and regulatory uncertainty, financing needs and dilution, dependence on third parties, intellectual-property exposure, and the possibility that actual results differ materially from forward-looking statements.
Important facts for investors to verify
- Confirm the issuer and period: this is AntriaBio’s March 31, 2017 Form 10-Q, not a Rezolute filing or a 2016-period report.
- Check the status and terms of subsequent fundraising, including the May 4 proceeds, the stated 2017 fundraising total and target, and resulting dilution.
- Verify the FDA IND submission and Phase 1 study timing and progress; the filing’s milestones were forward-looking plans.
- Review the going-concern disclosure and the company’s cash needs against actual cash burn and financing availability.
- Confirm court approval and implementation of the shareholder settlement and option cancellations.
- Assess whether the disclosed material weakness in disclosure controls was remediated.